Magnitude and factors associated with treatment interruption among HIV positive adolescents in selected public hospitals
| dc.contributor.advisor | Wakgari Deressaw | |
| dc.contributor.advisor | Abigiya Wondimagegnehu | |
| dc.contributor.author | Tessema Bayu | |
| dc.date.accessioned | 2026-06-22T15:12:37Z | |
| dc.date.available | 2026-06-22T15:12:37Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Background: According to United Nations Programme on HIV/AIDS report an estimate of 1.6 million adolescents aged 10 to 19 were living with human immune virus worldwide in 2018. Even though antiretroviral therapy programs have expanded rapidly and are now freely available, treatment interruption remains major public health problem in the country. Objective: To assess the magnitude and factors associated with treatment interruption among adolescents living with human immune virus in four public hospitals of Addis Ababa, Ethiopia. Method: A cross-sectional study using retrospective record review of patient charts and computerized medical records was conducted for a period of September 2020 to December 2022. Data was collected from 297 samples which are proportionately allocated in those four hospitals based on patient flow. Extraction form was used to collect data and data collectors were assigned from among the medical staff employed by the antiretroviral therapy clinics of selected hospitals. After being examined, cleaned, and downloaded into an Excel file, the gathered data was exported to SPSS Version 26.0 for additional analysis. Descriptive statistics were employed and Bivariate and multivariate logistic regression model were used to identify associated factors for interruption of antiretroviral therapy. Results: In this study 17.5% of participants (95% CI: 9.56–33.38) interrupted their antiretroviral therapy one or more times from their appointments. Oral thrush (AOR=3.34, 95% CI: (1.47, 7.59), not taking Cotrimoxazole prophylaxis (AOR=3.42, 95% CI: (1.42, 8.24), one year on antiretroviral therapy (AOR=3.75, 95% CI: (1.47, 9.55)), not taking Dolutegravir related medication (AOR:3.85, 95% CI: (1.60, 9.27), and world health organization stages 1 and 2 (AOR=3.50, 95% CI: (1.25, 9.78) and (AOR=3.52, 95% CI: (1.02, 12.12) respectively were found to be significantly associated with this variables. Conclusion: nearly one in five adolescents living with human immune virus interrupted their antiretroviral therapy. To increase ART retention and meet the 2030 HIV/AIDS eradication strategy, we suggest several key recommendations for ministry of Health and other responsible program implementers | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/8320 | |
| dc.language.iso | en | |
| dc.publisher | Addis Ababa Universtity | |
| dc.subject | Interruption in treatment | |
| dc.subject | Determinants | |
| dc.subject | Antiretroviral therapy | |
| dc.subject | HIV/AIDS | |
| dc.title | Magnitude and factors associated with treatment interruption among HIV positive adolescents in selected public hospitals | |
| dc.type | Thesis |